[A19-102] Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55
Last updated 06.03.2020
Project no.:
A19-102
Commission:
Commission awarded on 09.12.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Adults with HIV-1 infection whose virus has no known or suspected resistance to integrase inhibitors or lamivudine
Now proof of considerable (before: minor) added benefit for treatment-naive adults with HIV-1 infection
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-103 | Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55 | Commission completed |
| A19-55 | Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-06 A G-BA decision was published.